Mobiler Linearbeschleuniger für die Krebstherapie - 500 Beiträge pro Seite

[liscitrader]

Die Firma ist in einem Wachstumssegement tätig mit fast keinen Konkurrenten und einer etablierten Technologie, die schon an ca. 20 Krankenhäusern eingesetzt wird -- u.a. bei der Stanford University und der Mayo Clinic. Für nachfolgende Strahlentherapie bei Brustkrebsoperationen könnte es zum Standard werden -- dabei wird im Gegensatz zu normalen Anwendungen die Therapiedosis noch während der Operation verabreicht. Bei den neu etablierten Brustzentren in Deutschland kann sich jeder ausrechnen was dies bedeuten könnte. www.intraopmedical.com

[traumstrand]

Vergiss Deutschland, da sorgt schon das Bundesamt für Strahlenschutz (sic!) dafür, daß wg. Formalien in den nächsten 3-5 Jahren so ein Gerät nicht in Betrieb geht...

Gruß, ts.

[bert408]

nicht umsonst hat die fa. ums ag ihre deutsche beteiligung veräußert und konzentriert sich jetzt auf das hochlukrative geschäft in usa und südamerika. in ein paar jahren wird deutschland entwicklungsland, wenn wir so weitermachen

[liscitrader]

Antwort auf Beitrag Nr.: 25.529.414 von bert408 am 19.11.06 17:04:46

Danke für die Info -- meiner Ansicht nach gibt es mittelfristig Kunden in Zentraleuropa dafür. Warten wir mal ab.
UMS AG ist übrigens ein schlechtes Beispiel -- die sind Dienstleister und keine Hersteller und auf einem Sektor tätig (Lithotripsie), der etablierte Technik einsetzt. Also eher für Kunden, die sich bestimmte Anlagen nicht leisten konnten oder über zu wenig Patienten verfügten, um sich selber eine Anlage anzuschaffen.
Die Anlage ist übrigens selbstabgeschirmt - steht zumindest so geschrieben - heisst allerdings nicht, dass es keine Probleme mit dem Strahlenschutz gibt bzw. geben könnte.

[bodobodo]

Antwort auf Beitrag Nr.: 25.526.529 von traumstrand am 19.11.06 14:47:03

es scheint wohl schon einige positive Rückmeldungen hinsichtlich Strahlenschutz zu geben, d.h. als einziger Anbieter kann eine nennenswerte Anzahl von Patienten ohne Zusatzinvestitionen behandelt werden

Gruss Bo

[liscitrader]

Neuester Pressebericht (na ja ist auch schon vom 15.11.) -- hört sich auf jeden Fall sehr vielversprechend an.



New Study Shows Intraoperative Electron-Beam Radiation Therapy (IOERT) -- When Used with a Radiation Sensitizer -- Can Provide Long-Term Survival in Inoperable Pancreatic Cancer
Wednesday November 15, 8:30 am ET
Randomized Trial Shows that IOERT, When Used in Combination with a Radiation Sensitizer, Achieved a Three-Year Survival of 23% Versus 0% for Those Not Receiving the Sensitizer

SUNNYVALE, Calif.--(BUSINESS WIRE)--Inoperable pancreatic cancer is a devastating disease. More than half of the patients who contract this disease die within the year and nearly all succumb to the disease within three years. Until now, medical technology could offer little to these patients. Now, a randomized clinical trial shows that Intraoperative Electron-Beam Radiation Therapy or IOERT, the application of radiation therapy in the operating room during surgery, when used with a radiation sensitizing drug, may offer hope for this dread disease. This important, but little noticed study, was recently cited in a presentation given by Dr. Phillipe Calvo during a refresher course on IOERT presented on November 7, 2006 at the Annual Meeting of the American Society of Therapeutic Radiation Oncology (ASTRO).
ADVERTISEMENT

Dr. Katsuyuki Karasawa, chief of radiation oncology at the Tokyo Komagome Metropolitan Hospital in Tokyo, Japan, was the lead investigator on this landmark study. In the study, forty-five patients with inoperable pancreatic cancer and who received pancreatic by-pass surgery were randomized to receive either IOERT alone or IOERT with a radiation sensitizer. After surgery, all of the patients received external beam radiation therapy (EBRT). Of the patients that received IOERT plus the sensitizer, 23% were alive after three years, versus none for the group that received IOERT alone.

"These results are extremely encouraging for this very difficult-to-treat group of patients," said Dr. Karasawa. "It is not yet a cure for this disease, but for the first time patients with inoperable pancreatic cancer can be offered hope and a chance to extend their lives."

Dr. Joe Hsu, radiation oncologist at the University of California at San Francisco said, "The idea of combining chemotherapy and intraoperative radiotherapy has been presented at various international meetings, however this is the first clinical trial that proves this concept to be not only feasible but also has survival advantage. Similar combination of intra-operative radiotherapy and chemotherapy should be tested in other sites such as lung, abdomen and pelvis."

Donald A. Goer, president and CEO of IntraOp Medical Corporation which manufacturers Mobetron, the first OR-ready, fully mobile, self-shielding IOERT system, said, "These results are quite exciting, not only because of the survival benefits provided to these very difficult-to-treat patients, but because these results also demonstrate that radiation sensitizers can potentiate IOERT and make IOERT treatments even more effective. Many clinicians have long believed that radiation sensitizers are most effective when used with radiation given in a single dose, such as with IOERT. However, this is the first randomized clinical trial to demonstrate that it indeed works. IntraOp Medical, in addition to manufacturing and distributing Mobetron, also owns the rights to Etanidazole, an FDA approved Phase III radiation sensitizer. These results are encouraging for us as well."

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.


Contact:
For IntraOp Medical Corporation, Sunnyvale
Media Contact:
Affect Strategies
Courtney Chauvin, 212-398-9680 x142
[e-mail]
or
Investor Contact:
Emerging Markets Consulting, LLC
Jim Painter, 321-206-6682
[e-mail]

[UH1d]

Klingt hier sehr interessant alles ,werde sie beobachten.
Schaut euch imgg.ob an, Röntgen in 3D Realtime.
Neues in der Medizin ist immer gut.
Grüße

[liscitrader]

IMGG.OB ==> Habe ich mir mal angeschaut -- sieht auf den ersten Blick ganz gut aus.

Was fehlt war:
- kene tomogaphischen Bilder nur "Standard" - Röntgen
- keine Infos zu den Patenten
- keine Infos zu med. Institutionen, die das schon getestet haben
- kein Mitarbeiter mit einem "Science"-Degree

Muss man einfach sehen.

Ein CT in Deutschland kostet übrigens nur ca. EURO 200.000 neu (2-4 Zeilen).

[UH1d]

Antwort auf Beitrag Nr.: 25.633.903 von liscitrader am 23.11.06 21:33:20

Ich find die Bilder schon gut auf der Homepage

http://www.imaging3.com/image_gallery

zu den letzten Punkten gebe ich Dir Recht und das macht meine Phantasie aus, es wäre schlimm alles wär rechtens und konform!
Wo ist die Phantasie?
Grüße
Hohes Risiko evtl hoher Gewinn durch ene gute Geschichte im vorhinein?!
Grüße

[UH1d]

Antwort auf Beitrag Nr.: 25.633.903 von liscitrader am 23.11.06 21:33:20

http://www.imaging3.com/dominionspecsheet.html

Guter Preis!

[liscitrader]

Antwort auf Beitrag Nr.: 25.635.318 von UH1d am 23.11.06 22:07:36

Ich habe die Bilder schon auch gesehen, aber dass sind ganz stinknormale Röntgenbilder -- da ist kein Schnittbild dabei. ... und glaub mir davon verstehe ich wirklich was.

Ich will das nicht schlecht reden, sondern nur auf die Diskrepanz zwischen der Spezifikation und der Darstellung hinweisen.

Wir sollten das einfach beobachten. Ich bin nächste Woche auf der RSNA in Chicago (www.rsna.org) und schau mich mal um, ob die einen Stand haben. Ich berichte dann wieder.

Ansonsten sollten wir jetzt vielleicht wieder über mobile und intraoperative Linearbeschleuniger diskutieren.

[liscitrader]

Antwort auf Beitrag Nr.: 25.635.490 von UH1d am 23.11.06 22:11:30

Ich habe die Firma gefunden -- auf der RSNA -- http://rsna2006.rsna.org/rsna2006/V2006/exhibitor_list/displ…
Werde mir das wie gesagt nächste Woche mal LIVE anschauen.

[UH1d]

Antwort auf Beitrag Nr.: 25.636.621 von liscitrader am 23.11.06 22:39:03

Klingt gut!
Danke und Grüße

[liscitrader]

Antwort auf Beitrag Nr.: 25.627.012 von liscitrader am 23.11.06 18:24:54

Nächster Pressebericht zu IOPM.OB -- INTRAOPMEDICAL -- selbst die Chinesen erkennen den Sinn dieser Therapie -- vielleicht werden die Deutschen das auch bald

____________________________________________________________

First Mobetron in China to Be Used in New National Lung Cancer Initiative
Tuesday November 28, 8:30 am ET
IOERT to Play Prominent Role in Treatment of Lung Cancer in China

SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation (OTCBB: IOPM - News), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced that Mobetron® and IOERT will form an integral component in the Chinese Government's new initiative to combat lung cancer. Mobetron is a proprietary, mobile electron-beam instrument designed for Intraoperative Electron Radiation Therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery.
ADVERTISEMENT

Lung cancer is a major worldwide health problem and, with more than 400,000 cases per year, is by far China's most prevalent cancer. If left unchecked, experts estimate that within ten years, more than half of the world's lung cancer cases will occur in China. The current incidence of lung cancer in the United States is 174,000 cases per year and 163,000 patients die of this disease in the U.S. For this reason, the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences and the Peking Union Medical College (Beijing Tumor Hospital) has been designated by the Chinese Ministry of Health to become the research and development center for the treatment of lung cancer in China under the Lung Cancer Initiative. Other institutions will focus on early diagnosis and prevention.

Dr. He Jie, Vice-Dean of the Medical Center and Chief of Thoracic Surgery at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences and the Peking Union Medical College was appointed by the Ministry of Health to lead the treatment and research efforts in combating lung cancer in China. Beijing Tumor Hospital conducts more than 1,200 surgeries for lung cancer each year and Dr. He is recognized as one of the world's leading thoracic surgeons and researchers.

"We intend to use Mobetron and IOERT to provide a precise method of dose escalation for our surgical lung cancer patients," said Dr. He. "In lung cancer, metastatic failure is still the major problem, but we have made significant advances in the chemotherapy that we can offer patients. To be successful in this disease, we also need to focus on improving local control which will, incidentally, also help reduce the formation of metastases."

Dr. He continued, "Because the thorax has many radiation sensitive structures, escalating the dose to achieve local control of the tumor even through sophisticated radiation techniques available today, is not easy. IOERT escalates the dose at the time of surgery when residual tumor cells are most sensitive to destruction. This is where Mobetron can play a role."

When detected early, the current treatments for lung cancer can be effective and the patient's prognosis is significantly better than when detected in the later stages of the disease. For example, patients with Stage I lung cancer have a 60 - 70% five-year survival, while those with more advanced Stage III disease have only a 15% five-year survival.

The Lung Cancer Initiative was officially inaugurated on October 20 and 21, 2006, by the Vice-Minister of Health, Dr. Huang Jiefu, himself a surgeon, at a special symposium. Prominent lung cancer researchers and practitioners throughout China came together to share their research, to discuss the status of lung cancer both in China and the rest of the world, and to suggest promising avenues of research for the treatment of this disease.

Together with Dr. Wang Liu-Hua, Professor and Deputy Director of Radiation Oncology at the Cancer institute, protocols using IOERT will be developed for every stage of lung cancer in which surgery is employed.

"This concerted effort by the Chinese Government to establish a world-class lung cancer research and treatment facility can have widespread implications not only for lung cancer patients in China but for cancer patients throughout the world," said Dr. Donald A. Goer, President and CEO of IntraOp Medical Corporation. "Previous IOERT studies involving lung cancer have been limited in scope and involved relatively few patients. Though the published results were encouraging, some showing two or three times the five-year survival over that achieved with conventional approaches alone, it was difficult to draw definitive conclusions concerning the proper role of IOERT in the treatment of this disease. This initiative will finally give us the answers."

About Beijing Tumor Hospital

Beijing Tumor Hospital is the teaching, research and treatment hospital of the Beijing University Medical School, focusing on the prevention, treatment and rehabilitation of cancer patients. With 400 beds, the institution treats 6,000 patients per year. In addition to a modern radiotherapy department, the center boasts one of the most advanced tumor molecular biology laboratories in the world.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.


Contact:
Media:
Affect Strategies
Courtney Chauvin, 212-398-9680 x142
[e-mail]
or
Investor:
Emerging Markets Consulting, LLC
Jim Painter, 321-206-6682
[e-mail]

[liscitrader]

European Medical Studies: Shorter Treatment Cycles, Improved Tumor Control and Longer Life Expectancy for Cancer Patients Treated with IOERT
Tuesday December 19, 10:29 am ET
Intraoperative Electron-Beam Radiation Therapy (IOERT) may soon shorten treatment cycles from 5-7 weeks to 2 minutes for some breast cancer patients and increase survival rates for rectal, pancreatic and sarcoma cancer patients

SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation (OTCBB: IOPM - News) today announced the results of several cancer research studies that were presented at the European Society of Surgical Oncology (ESSO) Conference, November 30 to December 3 in Venice, Italy, by members of the International Society of Intraoperative Radiation Therapy (ISIORT).

ADVERTISEMENT
These studies examined the efficacy of intraoperative electron-beam radiation therapy (IOERT) for the treatment of breast cancer, rectal cancer, pancreatic cancer and sarcomas for patients treated at various European centers. The results of individual studies were 'pooled' by ISIORT to provide greater statistical significance to the results of individual studies with patients that were treated with identical therapies. Some of the studies are still ongoing but preliminary results show significant improvements in areas such as local tumor control, shorter treatment cycles and longer life expectancy. The studies are summarized below:

Breast Cancer: Two Minutes of IOERT to Replace Five Weeks of Radiation Therapy

The European Institute of Oncology (EIO) is conducting a randomised trial on IOERT for early stage breast cancer. The EIO is testing whether for a select group of women with early stage breast cancer if the conventional treatment of five to seven weeks of external beam radiation, after the woman has healed from the surgical removal of the tumor, can be replaced by a two minute treatment of IOERT. The study is focusing on women over the age of 48 with small tumors and negative nodes.

The report on this study was given by Dr. Giovanni Ivaldi, radiation oncologist at the EIO. The study is expected to be completed by the end of this year and the final results will be reported in about 24 months, after the data has matured. Dr. Ivaldi reported on the results of 590 patients treated with IOERT as the sole radiation treatment for early stage breast cancer at the EIO. The patients treated with IOERT and surgery alone appeared to be doing as well as conventionally treated patients but, it will be another 24 months before all of the answers concerning this promising approach will be proven by the randomized trial.

Dr. Umberto Veronesi, director of the EIO in Milan, Italy, said, "Intraoperative radiotherapy is becoming a substantial component of the methods and procedures for the treatment of cancer because of the new mobile linear accelerators. They are very easy to use. Now, breast cancer, abdominal tumors, rectal cancer, pancreatic cancer, cervical cancer and gynecological tumors can be treated intraoperatively. This represents a new course in therapy."

Rectal Cancer: Five-Year Survival Rates Increase from 25% to 60% with IOERT

At Catharina Hospital, in Eindhoven, The Netherlands, Dr. Harm Rutten, surgical oncologist, is heading the pooled analysis study for patients with locally advanced rectal cancer. This study showed that patients treated with IOERT achieved a five-year local control of 87% and had a five-year survival of over 60%. This is in marked contrast to conventional treatment approaches without IOERT that typically achieve a five-year local tumor control of less than 50% and survival of only about 25%. Patients who fail to achieve local tumor control in rectal cancer may require further surgery, additional hospitalization and alternative treatments.

According to Dr. Rutten, the results of this study, which pooled the data from four institutions and more than 600 patients, show the important role that IOERT plays in both local control and in survival for advanced rectal disease. "In The Netherlands, we are already writing protocols which require IOERT to be given to all Dutch patients who have rectal recurrences. Recurrent rectal cancer is even a more difficult disease to treat than locally advanced rectal cancer. With the new mobile IOERT technology available, it is convenient and easy to deliver. It should not be long before all major cancer centers can offer this critical treatment to their patients," said Dr. Rutten.

Breast Cancer: IOERT 'Boost' Achieves 99.6% Tumor Control

Dr. Felix Sedlmayer, professor and chairman of radiation oncology at the University of Salzburg, Austria, presented pooled data for 1100 early stage breast cancer patients from six European centers treated using IOERT as a 'boost'. In a boost treatment, IOERT is given during the time of surgery after the removal of a cancerous tumor and additional external beam radiation is given to the patient after healing from the initial surgery. The advantage of the IOERT boost, also known as the 'bio-boost', is that it can be given to all women who are candidates for breast conserving therapy, irrespective of age or nodal status, size or even grade of the tumor. More than half of the women in the pooled analysis had one or more of these adverse factors. With a median follow-up of 53 months, there were no recurrences at the site of the IOERT boost and only four in-breast recurrences resulting in in-breast tumor control of 99.6%. At the University of Salzburg, the bio-boost is already the standard of care for early stage breast cancer patients.

Sarcomas: Shorter Treatment Cycles, Fewer Complications and Longer Survival Rates with IOERT

Dr. Robert Krempien, professor and chairman of radiation oncology at the University of Heidelberg, Germany, presented the results of a study on 255 patients with extremity sarcomas. In this study, radiation therapy combined with surgery (to remove the tumor) was used to avoid surgical amputation of the effected limb. Sarcomas are typically quite large and while they can be treated with external beam radiation or brachytherapy, IOERT has the advantage of being delivered at the time of surgery when the boost dose is more effective, is very uniform and can reduce the amount of external radiation therapy that is required. With a median follow-up of 61 months, Dr. Krempien reported local control and survival rate of 77% and 78% respectively. These results compare quite favorably with conventional boost techniques.

Dr. Krempien also reported on the use of IOERT to treat 123 retroperitoneal sarcoma patients. These sarcomas are large tumors in the abdomen. It is very difficult to achieve local control and long-term survival in patients with this disease. Of the patients in the study, two-thirds had recurrent tumors, 67% were high grade tumors (more virulent) and more than half the patients had tumors larger than 10 cm. Despite these unfavorable characteristics, the analysis showed a five-year survival of 58%, which compares very favorably to conventional approaches for this tumor type.

Pancreatic Cancer: 73% Five-Year Local Control Rates for Patients Treated with Preoperative Chemoradiation Coupled with IOERT

Dr. Vincenzo Valentini, professor of radiation oncology at the Catholic University in Rome, presented the pooled analysis for pancreatic cancer, one of the most difficult cancers to treat effectively, by any method. (In the United States, there are 30,000 cases of pancreatic cancer each year and the annual death rate from this disease is approximately 29,100.) The 185 patients in the European study were treated by three different IOERT techniques: IOERT alone; IOERT followed by post-operative radiation therapy with or without chemotherapy, or pre-operative chemoradiation therapy followed by IOERT. The five-year local control for all patients was 23%, but increased to 58% for patients who also received chemotherapy and was 73% for those who received pre-operative chemoradiation therapy plus IOERT. In pancreatic cancer, patients that achieve local control generally also have pain relief for most of their lives. The five-year survival was 22% for patients that received pre-operative chemoradiation therapy but only 6% for those that had IOERT alone. The pooled analysis clearly demonstrates that the preferred approach for treating pancreatic cancer is preoperative chemoradiation therapy followed by IOERT.

More information on these studies can be found on the ISIORT website, www.isiort.org,

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

[liscitrader]

IntraOp Medical Releases Fiscal 2006 Results
Wednesday December 27, 1:35 pm ET
Sales Increased by More Than 50% over FY2005, Orders for Mobetron Double

SUNNYVALE, Calif.--(BUSINESS WIRE)--IntraOp Medical Corporation (OTCBB:IOPM - News) issued record financial results for its fiscal year ended September 30, 2006.
ADVERTISEMENT


Donald A. Goer, Ph.D., President and CEO of IntraOp, stated, "In the fourth quarter of FY2006 we shipped three Mobetron systems. The revenue from these sales and our growing service operations resulted in the best quarter in our history, and contributed to a record year for sales, orders and backlog. We start FY2007 with a backlog of three orders, and the continuing publication of positive clinical results on intraoperative electron-beam radiation therapy is strengthening the demand for Mobetron. We look to FY2007 to show still more significant improvements in performance. We have added additional sales and service staff, and feel confident that we will achieve our targets for the year."

The Company recorded $5.98 million in sales for the year, with an operating loss of $2.43 million and a net loss of $7.16 million. The fourth quarter had sales of $3.67 million, with break even operations and a net loss of $1.14 million.

[liscitrader]

Antwort auf Beitrag Nr.: 26.630.608 von liscitrader am 01.01.07 22:21:07

Ist zwar schon etwas älter --- aber gibt einen guten Hinweis auf die Zukunft der Firma.
Im Gegensatz zu vielen der OTC-Werte hat die Firma tatsächlich ein Produkt und verkauft es sogar mit einem internationalen Fokus.
Nun haben sie auch einen Vertriebsmann nur für die Nordländer Europas eingestellt.
Mal schaun wann die etwas an die Top-Institutionen in Deutschland verkaufen (Unis Heidelberg, Tübingen, München, Berlin, Köln, Münster).



_________________________________________________________

CORRECTING AND REPLACING IntraOp Medical Announces Record Sales, Expansion into New Markets and Development of Sales Organization
Wednesday January 31, 4:02 pm ET

SUNNYVALE, Calif.--(BUSINESS WIRE)--Second graph, first sentence of release should read: In 2006, IntraOp sold five and accepted orders for eight Mobetron self-shielding linear accelerators for administering electron-beam radiation therapy during cancer surgery. (sted In 2006, IntraOp sold eight Mobetron self-shielding linear accelerators for administering electron-beam radiation therapy during cancer surgery.)
ADVERTISEMENT

The corrected release reads:

INTRAOP MEDICAL ANNOUNCES RECORD SALES, EXPANSION INTO NEW MARKETS AND DEVELOPMENT OF SALES ORGANIZATION

2006 marks record sales for IntraOp as the medical community further embraces intraoperative electron-beam radiation therapy (IOERT) for the treatment of cancer

IntraOp Medical Corporation (OTCBB: IOPM - News), announced today the company achieved record sales in 2006 and is poised for continued growth and success in 2007 with the development of its sales infrastructure, expansion of its distributor relationships and rise in interest in intraoperative electron-beam radiation therapy among cancer treatment professionals.

In 2006, IntraOp sold five and accepted orders for eight Mobetron self-shielding linear accelerators for administering electron-beam radiation therapy during cancer surgery. The company accepted orders from U.S. cancer centers as well as Belgium, Poland, China, Italy, Japan and the Netherlands. To date, the Mobetron is being used in seven countries and has helped invigorate interest in IOERT for the treatment of a broad spectrum of cancers in various stages of severity. Last year, a number of critical studies were published illustrating the effectiveness of IOERT from the The European Institute of Oncology (EIO), Catharina Hospital, in Eindhoven, The Netherlands, University of Heidelberg, Germany, and the Catholic University in Rome, Italy.

IntraOp has doubled its production capacity, added a distributor in Scandinavia, Admedico, and opened a sales office in Cologne, Germany, to meet the demand for Mobetrons. In addition, IntraOp added three seasoned medical-equipment salespeople in the U.S. and one in Europe:

M. Dean Whitney, Eastern Region Sales Manager

Thomas C. Rhea, Central Region Sales Manager

Charles E. Medalie, Western Region Sales Manager

Stefan Dirks, Director of Sales, Northern Europe

All four salespeople each have more than 25 years experience in medical imaging and radiation oncology equipment sales with companies such as Varian, Nucletron, Impac, Siemens and Nomos.

The company has also increased its activity in professional forums to raise awareness for and educate doctors, radiation oncologists, surgical oncologists and hospital administrators to the medical, monetary and marketing benefits that IOERT devices can bring to cancer treatment centers and their patients.

IntraOp met with more than 130 of the nation's leading radiation oncologists and international delegates at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in November 2006 in Philadelphia, PA. More than 100 surgical oncologists attended the International Society of Intraoperative Radiation Therapy's (ISIORT) special session disclosing clinical research results at the European Society of Surgical Oncology's (ESSO) 13th Congress in Venice, Italy, in the same month. At both events, IntraOp met with prominent researchers and medical practitioners that are fighting cancer on a daily basis with their patients. Italy in particular is at the forefront of IOERT usage. There are currently 18 hospitals in Italy using some form of intraoperative radiation therapy - three are using the Mobetron.

"In 2006 we laid the foundation for strong growth for IntraOp," said Donald A. Goer, president and CEO of IntraOp Medical Corporation. "The infrastructure that we put into place - doubling our production capacity, expanding our sales team, investing in public relations and marketing - is designed to enable us to take advantage of the growing interest in and demand for IOERT solutions. The Mobetron is fundamentally changing the way cancer patients are being treated today and positively impacting their survival."